ψαμιξιγ 10 ξ"β
|
ων δϊψετδ αΰπβμιϊ: Revlimid ® 10 Mg.
ξητωιν ϊψετδ ΰηψϊ? λπρε μΰιπγχρ δϊψετεϊ »
|
|
 αρμ δαψιΰεϊ
φεψϊ ξϊο
PER OS
ξιπεο
Capsules
ωιξεω αϊψετδ
REVLIMID is indicated for 1. Treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. In combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.3. Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib
ξρτψ ψιωεν
140 46 31661 16
ιφψο
Celgene Europe Ltd, Uk
ϊεχσ ψιωιεο μϊψετδ
07/2014 - 04/2024
ηεξψ τςιμ
|
ψιλεζ / λξεϊ αιηιγϊ ξιπεο
|
Lenalidomide |
10 MG |
ΰψιζδ
|
λξεϊ αΰψιζδ
|
ηιι ξγσ
|
ϊψετϊ ξψων
|
Blister pvc/pctfe |
21 x CAPSULES |
36 ηεγωιν |
λο |
|
|
|